EUCTR2014-004376-39-Outside-EU/EEA进行中（未招募）不适用
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
CB Biosciences, Inc.0 个研究点目标入组 25 人开始时间: 2015年2月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects with a diagnosis of epilepsy on up to three concomitant anti-epileptic drugs
- •- Subjects on Levetiracetam immediate release (IR) can be enrolled if on a stable dose for 7 days
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •- Subjects with a history of status epilepticus within 3 months of Visit 1
- •- Subject has difficult venous accessibility
研究者
相似试验
招募中
3 期
An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurativaHidradenitis Suppurativa2024-511035-10-00UCB Biopharma347
已完成
3 期
A clinical trial to study the effect of FDC of Azelastine and Mometasone Nasal Spray in Patients with Seasonal Allergic Rhinitis (symptoms similar to those of a cold such as runny nose and sore throat, caused by an allergic reaction to an allergen such as dust, plant pollens or animal dander)CTRI/2013/01/003334Glenmark Pharmaceuticals Ltd560
已完成
不适用
A Multicenter, Open-label, Two-arm Parallel-group, Non-inferiority Investigator-Initiated Trial to compare efficacy and safety of LObeglitazone or linagliptin add-on triple therapy in Type 2 Diabetes Mellitus patients under stable treatment with MEtformin and emPAglifloziEndocrine, nutritional and metabolic diseasesKCT0004509Chonnam National University Hospital Hwasun Hospital136
进行中（未招募）
2 期
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)Paroxysmal nocturnal hemoglobinuriaD006457JPRN-jRCT2051210179Sakagami Yohei81
进行中（未招募）
1 期
BCX9930 treatment in patients with an inadequate response to C5 inhibitorsEUCTR2020-004438-39-SKBioCryst Pharmaceuticals Inc81